MARKET

INVA

INVA

Innoviva
NASDAQ
18.22
+0.24
+1.33%
After Hours: 18.23 +0.01 +0.06% 16:02 02/13 EST
OPEN
18.04
PREV CLOSE
17.98
HIGH
18.33
LOW
17.95
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
21.28
52 WEEK LOW
14.33
MARKET CAP
1.14B
P/E (TTM)
26.49
1D
5D
1M
3M
1Y
5Y
1D
Innoviva (INVA) Shares Cross Below 200 DMA
NASDAQ · 2d ago
Weekly Report: what happened at INVA last week (0203-0207)?
Weekly Report · 3d ago
Weekly Report: what happened at INVA last week (0127-0131)?
Weekly Report · 02/03 09:12
Weekly Report: what happened at INVA last week (0120-0124)?
Weekly Report · 01/27 09:12
Weekly Report: what happened at INVA last week (0113-0117)?
Weekly Report · 01/20 09:11
Innoviva (NASDAQ:INVA) investors are up 4.7% in the past week, but earnings have declined over the last five years
Simply Wall St · 01/16 10:00
Weekly Report: what happened at INVA last week (0106-0110)?
Weekly Report · 01/13 09:12
Weekly Report: what happened at INVA last week (1230-0103)?
Weekly Report · 01/06 09:12
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.